Should You Add Illumina Stock to Your Portfolio Now?

Illumina Inc. ILMN is well positioned for growth in the coming quarters, driven by strategic execution focused on growing its core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing momentum in oncology is boosting clinical growth. Additionally, a strong solvency looks encouraging. However, input-cost volatility may constrain incremental margin expansion over the next several quarters.

Over the past year, this Zacks Rank #2 (Buy) stock has surged 129.6%, well ahead of the industry’s 24.6% growth and the S&P 500 composite’s rise of 20.1.%.

The renowned biotechnology company has a market capitalization of $27.82 billion. ILMN’s earnings yield of 2.4% is well ahead of the industry’s -14.9% yield. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 9.7%. 

Let’s delve deeper.

Tailwinds Supporting ILMN Stock

Sharpened Focus on Core Genomics: Following the June 2024 GRAIL spin-off, Illumina remains centered on its core sequencing franchise while extending into multiomics, data and software. The second-quarter 2026 results offered further evidence that the strategy is beginning to gain traction. Revenues rose 9.5% year over year to $1.16 billion, supported by continued demand across the business. 

Management raised full-year 2026 revenue guidance to $4.60-$4.64 billion and adjusted earnings per share (EPS) guidance to $5.30-$5.40 while maintaining adjusted operating margin projection of 23.4-23.6%. The company continues to target high-single-digit revenue growth in 2027, supported by its core sequencing business, multiomics and data offerings. Together, these developments keep Illumina on track with its longer-term growth and profitability framework and support continued progress toward its stated targets.

Oncology Portfolio and Workflow Expansion Support Adoption: Illumina is broadening the workflows that can run within its sequencing ecosystem as clinical customers adopt larger, more data-intensive assays. In the second quarter of 2026, oncology continued to lead clinical growth, with therapy selection remaining the largest contributor and molecular residual disease (MRD) beginning to gain momentum.

The company also launched a whole-genome MRD research workflow for NovaSeq systems in early access, designed to shorten assay-development timelines and lower development costs. Beyond sequencing, the company launched StrataMap Spatial and continued to expand SomaScan and SomaSeq after the SomaLogic acquisition. 

Image Source: Zacks Investment Research

BioInsight has begun generating revenues through the Billion Cell Atlas, which has delivered more than 300 million cells and added three partners after quarter-end, bringing the total to six biopharma partners. These offerings broaden customer use cases and support Illumina’s longer-term multiomics and data strategy.

Favorable Solvency: Illumina ended the second quarter of 2026 with combined cash, cash equivalents and short-term investments of $1.04 billion compared with $1.09 billion at the end of the first quarter. 

Current debt was $500 million, broadly unchanged sequentially, while long-term debt remained at $1.49 billion. Gross debt was approximately 1.6 times last-12-month EBITDA, reflecting manageable leverage. The company’s liquidity remains sufficient to support operations, strategic investments and capital returns.

What Ails ILMN Stock?

Macroeconomic Cost Risks Remain: Illumina continues to operate in a higher-cost environment shaped by tariffs, freight and component inflation. In the second quarter of 2026, adjusted gross margin was 68.2%, down 120 bps year over year, as a heavier instrument mix, higher freight and memory costs, and lower-margin SomaLogic revenues offset operating initiatives and lower tariff costs. Adjusted operating margin was 22.5%, down 130 bps year over year. Tariffs, shipping costs and memory costs are expected to continue affecting results, leaving margins sensitive to product mix and external cost volatility.

ILMN Stock Estimate Trend

The Zacks Consensus Estimate for ILMN’s 2026 EPS has increased 2.3% to $5.34 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $4.62 billion, calling for a 6.4% rise from the year-ago reported number.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Globus Medical GMED, Veracyte VCYT and Teleflex TFX.

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Teleflex, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research